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INTRODUCTION
The Pacific Vascular Symposium 6: The Venous
Ulcer Summit in perspective
Peter Henke, MD, on behalf of the Pacific Vascular Symposium 6 faculty, Ann Arbor, MichChronic venous disease is extremely common, and
varies in severity from asymptomatic varicosities to severe
ulceration and disability. The venous stasis ulcer (VSU) is
an under-recognized and undertreated disease. The reasons
for this are multifactorial: inadequate graduate and post-
graduate training, the diffuse nature of the disease presen-
tation, treatment administered by numerous specialties,
and the lack of understanding of preventability and treat-
ment, underscored by a lack of focused interest by many
practitioners. Together, these factors slow progress for
patients worldwide.
The goal of Pacific Vascular Symposium 6 (PVS6) was
to lead a call to action, with a group of interested interna-
tional experts in venous disease, to formulate a doable and
achievable plan to reduce VSU incidence by 50% in 10
years. This is a challenging goal, but we believe it is possible
within the current health care system and with the preven-
tion, education, and treatment tools currently available to
us. The charge of the PVS6 faculty was to arrive at a
reasonable number of critical issues and devise detailed
action plan, all within a specified timeframe. This meeting
was intensive and tightly structured to keep the focus of the
groups on task and to have the formal plan completed
within the timeframe of 4 days.
What follows in this Journal of Vascular Surgery® sup-
plement are the six primary articles. The following manu-
scripts are not simply current reviews of the topical litera-
ture, but are issue and process focused. Also important, the
manuscripts reflect each groups’ input and collective
knowledge and are not by any means the solo product of
the lead writers. The compilation at the end of this supple-
ment are extended abstracts voluntarily presented by
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up-to-date topical information related to venous disease
and VSU.
Details from the steering committee organization and
the precise structure of the PVS6 meeting format are de-
tailed by Dr Fedor Lurie. The background and legwork by
the steering committee was impressive and directly resulted
in the success of this group coming together with the
supplement presented here. More broadly, the concept of
getting a large and international group of experts together
and the format of the summit are important for those not
just with an interest in venous stasis ulceration. This type of
focused call to action amongst a multidisciplinary group
could be replicated for other common vascular problems,
such as peripheral arterial disease. Similarly, the American
Heart Association has done a very successful educational
initiative, “Get with the Guidelines,” that disseminates best
practices for treatment of myocardial infarction. Certainly,
education of the provider who takes care of the VSUpatient
is one of the overarching goals of this group.
Drs Gillespie and Kistner put forth a cogent and fo-
cused article on VSU epidemiology and pathophysiology,
but focus on tangible therapy, educational challenges, and
directed actions. This is not a comprehensive review, but
rather highlights avenues to improve delivery of care for
prevention and treatment. For example, a theme that un-
derlies much of the problem in VSU care is the lack of
coherent treatment for the patient and that VSU is a
lifelong disease. That is, after VSU healing, these patients
need to be monitored for life to prevent recurrence. This is
a paradigm shift, in that one dedicated physician should
manage these challenging patients.
Drs Neglen and Eklof review the role of primary venous
insufficiency on venous stasis ulceration. Their group iden-
tified four primary issues that, if addressed, could signifi-
cantly affect VSU occurrence, because ulceration does not
develop in most patients with mild venous insufficiency.
Thus, the key is identification of those at highest risk,
improving standardized ultrasound testing, and identifying
risks for progression and treatments to prevent progression
to VSU.
Drs Henke and Wakefield describe six critical issues in
postthrombotic syndrome, focusing on recurrent ipsilateral
deep vein thrombosis and advancing the need for several
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deep vein thrombosis clearance, as well as other issues with
interventional and medical therapy. Although not as com-
mon as primary venous insufficiency, the risk of VSU is
particularly high with deep vein thrombosis, and addressing
this disease is paramount.
Drs Passman and Elias synthesize perhaps the most
broad topics related to VSU prevention and therapy, with
the emphasis on nonmedical issues. The group details the
important issues, such as lack of general awareness of VSU
at multiple levels of care delivery, the poor coordination of
VSU care, the need for better understanding of the eco-
nomics and care for VSU patients (including the need for
comparative effectiveness), as well as a central organization
to coordinate these initiatives.
Lastly, a summary document details the nine critical
issues that came from the four groups (eliminating someoverlap) and the action items with a timeline. These are the
framework to achieve the overall goal of a 50% reduction in
VSU in 10 years.
This written supplement has several goals: First, to
establish the summary of action items and broadly broad-
cast these; second, to gain input from interrelated and
interested practitioners in this call to action and to be
inclusive; and third, to raise awareness for trainees, faculty,
and all practitioners who take care of patients with venous
disease to address this very common and significant prob-
lem. Although much of the educational initiatives and
guidelines can be directed from a central group such as this,
most of the true action items will need to occur locally, with
enthusiastic and committed practitioners in all of our clin-
ics, medical schools, and hospitals. This supplement is the
first step forward, but many more are needed to get to the
finish line.
